$SRDX (SurModics, Inc.)

$SRDX {{ '2016-01-11T16:04:08+0000' | timeago}} • Announcement

$SRDX acquired NorMedix for $14MM, including an upfront payment of $7MM, and up to $7MM based on the achievement of revenue and other value-creating milestones through Sept. 30, 2019. Other financial terms of the agreement were not disclosed.

$LLY {{ '2017-07-24T18:19:30+0000' | timeago}} • Announcement

$LLY and $NKTR have joined hands to co-develop NKTR-358, a novel immunological therapy discovered by the latter. NKTR-358, which achieved first human dose in Phase 1 clinical development in March, 2017, is potent in treating a number of autoimmune and other chronic inflammatory conditions.

$BMY {{ '2017-07-24T16:32:02+0000' | timeago}} • Announcement

$BMY said the U.S. Food and Drug Administration (FDA) has expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older.

$PFE {{ '2017-07-24T15:56:36+0000' | timeago}} • Announcement

$PFE's REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin, met its primary objective. PF-06439535 is being developed by $PFE as a potential biosimilar to Avastin. Results demonstrate equivalence in objective response rate in patients with advanced non-squamous non-small cell lung cancer.

$TFX {{ '2017-07-24T12:12:24+0000' | timeago}} • Announcement

$TFX said its Arrow Seldinger Arterial Catheterization Device received market clearance from the U.S. Food and Drug Administration (FDA). The new Seldinger Arterial Catheterization Device is indicated for short-term use. $TFX expects to launch the Arrow Seldinger Arterial Catheterization Device in US this year.

$ABBV {{ '2017-07-21T16:09:32+0000' | timeago}} • Announcement

$ABBV received positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for Humira (adalimumab) for the treatment of chronic non-infectious anterior uveitis in pediatric patients. Uveitis is an inflammation of the uvea, which includes the iris, choroid, and the ciliary body in eye.

$MCK {{ '2017-07-21T16:07:44+0000' | timeago}} • Announcement

Biologics, a unit of healthcare technology firm $MCK, said it will join the limited distribution network of $PBYI to promote the latter’s kinase inhibitor Nerlynx. The formulation is indicated for treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer.

$REGN {{ '2017-07-21T15:50:38+0000' | timeago}} • Announcement

$REGN and $SNY announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has given a positive opinion for the marketing authorization of Dupixent (dupilumab), recommending its approval in Europe for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

$MRK {{ '2017-07-21T15:21:07+0000' | timeago}} • Announcement

President Donald Trump announced that pharma giants $MRK and $PFE are collaborating with Gorilla Glass manufacturer Corning ($GLW) for manufacturing a new glass (Valor Glass), which is superior and reliable for the delivery of injectable drugs. Corning is planning to initially invest $500MM creating 1,000 jobs at 3 facilities in US.

$ABT {{ '2017-07-20T19:55:45+0000' | timeago}} • Webcast

For 3Q17, $ABT expects adjusted EPS of $0.64-0.66, with operational sales growth expected in the mid-single digits. At current exchange rates, the company expects operational sales growth to have a negative YoY impact of around 0.5%.

$ABT {{ '2017-07-20T19:45:56+0000' | timeago}} • Webcast

$ABT said that on a comparable operational basis, 3Q17 Established Pharmaceuticals sales growth is expected in the high double-digit, while in Nutrition, sales growth is expected in low single-digit. In Diagnostics, $ABT expects sales to increase mid-to-high single digits and in Medical Devices, sales is expected to increase double-digits.

$ABT {{ '2017-07-20T17:49:19+0000' | timeago}} • Announcement

$ABT raised its full year profit forecast backed by the intention of closing the Alere acquisition in 2017. The company raised its FY17 adjusted earnings from continuing operations guidance by $0.03 to a range of $2.43-2.53 per share. Reported EPS forecast was also raised from the range of $0.92-1.02 to $1.03-1.13, reflecting double-digit growth.

$ABT {{ '2017-07-20T17:36:53+0000' | timeago}} • Announcement

Declining operating earnings and rising costs and expenses hit $ABT 2Q17 earnings as much as 54%. Earnings plunged to $283MM or $0.15 from $615MM or $0.40 per share a year earlier. Sales, however, surged 24.4% on St. Jude Medical acquisition. On an adjusted basis, $ABT reported EPS above its previous guidance range at $0.62 per share.

$ABT {{ '2017-07-20T12:52:57+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q2 2017 Highlights

$HRC {{ '2017-07-19T14:11:03+0000' | timeago}} • Announcement

$HRC declared a dividend of $0.18 per share for 4Q17 payable on September 29, 2017, to shareholders of record as of September 15, 2017. The indicated annual dividend rate is $0.72 per share.

$BAX {{ '2017-07-18T14:01:55+0000' | timeago}} • Announcement

The BoD of $BAX declared a quarterly dividend of $0.16 per share of its common stock. The dividend is payable on Oct 2, 2017, to stockholders of record as of Sept 1, 2017.

$NKTR {{ '2017-07-18T13:13:43+0000' | timeago}} • Announcement

Pharma company $NKTR said a study on pain relief drug NKTR-181 demonstrated less abuse potential, compared to commonly used medicine oxycodone.  The study was designed to assess the relative oral abuse potential of the formulation at its maximum dose. The FDA has granted NKTR-181 fast track designation for treatment of moderate to severe pain.

$BAX {{ '2017-07-17T20:58:53+0000' | timeago}} • Announcement

$BAX appointed Cathy Smith, EVP and CFO of $TGT, to its BoD, bringing the total number of directors serving the company at this time to 13. Smith now also serves on $BAX's Audit Committee.

$PRGO {{ '2017-07-17T13:30:02+0000' | timeago}} • Announcement

$PRGO received final approval from the FDA for its AB rated Abbreviated New Drug Application referencing $ABBV's Androgel Topical Gel, 1.62% packets. The gel is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

$ABT {{ '2017-07-17T12:36:21+0000' | timeago}} • Announcement

$ABT is commencing a tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. at a price of $402 per share of Preferred Stock. The offer will expire at 11:59 pm, NYC time, on Aug 11, 2017. There is no financing condition to the offer.

$VRTX {{ '2017-07-13T12:31:35+0000' | timeago}} • Announcement

$VRTX announced that the Italian Medicines Agency has agreed to reimburse ORKAMBI (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older who have two copies of the F508del mutation. Effective immediately, hundreds of eligible patients in Italy will have access to this medicine.

Recent Transcripts

ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
NKTR (Nektar Therapeutics)
Tuesday, May 9 2017 - 9:00pm
HAE (Haemonetics Corporation)
Monday, May 8 2017 - 12:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
TFX (Teleflex Incorporated)
Thursday, May 4 2017 - 12:00pm
PFE (Pfizer Inc.)
Tuesday, May 2 2017 - 2:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, April 28 2017 - 12:30pm
RMD (ResMed Inc.)
Thursday, April 27 2017 - 8:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
ABBV (AbbVie Inc.)
Thursday, April 27 2017 - 1:00pm
SRDX (SurModics, Inc.)
Thursday, April 27 2017 - 12:30pm
BAX (Baxter International Inc.)
Wednesday, April 26 2017 - 12:30pm
SYK (Stryker Corporation)
Tuesday, April 25 2017 - 8:30pm
MMM (3M Company)
Tuesday, April 25 2017 - 1:00pm
ABT (Abbott Laboratories)
Wednesday, April 19 2017 - 1:00pm
NKTR (Nektar Therapeutics)
Wednesday, March 1 2017 - 10:00pm
TFX (Teleflex Incorporated)
Thursday, February 23 2017 - 1:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, February 9 2017 - 1:30pm

AlphaGraphics you may like